Agilent Technologies (A) Investor Day 2024 summary

Strategic transformation and growth initiatives

• Launched the Ignite transformation program to accelerate innovation, simplify operations, and expand market focus, building on a customer-centric organizational structure.

• Shifted from a product-centric to a market- and customer-focused structure, aligning business units to key end markets and high-growth segments such as Pharma & BioPharma, Clinical & Diagnostics, and Applied Markets.

• New structure aligns three business groups: Life Sciences & Diagnostics (LDG), Applied Markets Group (AMG), and Agilent CrossLab Group (ACG), each targeting specific market opportunities.

• Strategic M&A, including BioVectra, 6sense, and Sigsense, expands capabilities in CDMO services and AI-driven software, supporting growth in high-value segments.

• Sustainability initiatives include certified pre-owned instruments, circular economy programs, sustainable product design, and environmental impact labeling.

Financial guidance and performance outlook

• Achieved FY24 revenue of $6.5B, with a 26.4% non-GAAP operating margin and $5.29 non-GAAP EPS.

• Delivered 6% revenue CAGR and 13% EPS CAGR from FY20 to FY24, with margin expansion of 290 bps.

• Long-term guidance targets 5%-7% annual core revenue growth, double-digit EPS growth, and 50-100+ bps annual operating margin expansion.

• FY25 guidance projects net revenue of $6.79–$6.87B, core revenue growth of 2.5–3.5%, and EPS of $5.54–$5.61.

• Non-instrument revenue (services, consumables, software) now accounts for 64% of FY24 revenue, with attach rates up 400 basis points since 2020.

Business segment highlights and market opportunities

• LDG: $2.5B FY24 revenue, 19.6% margin, focused on advanced therapeutics, CDMO expansion, and oncology diagnostics.

• AMG: $1.3B FY24 revenue, 24.0% margin, leveraging leadership in PFAS, semiconductors, batteries, and high-growth adjacencies.

• ACG: $2.7B FY24 revenue, 33.7% margin, driving growth through services, consumables, digital solutions, and customer lifetime value.

• PFAS testing is a major growth driver, with over 20% growth in FY24 and significant runway as regulations expand.

• Regional growth strategies include double-digit CAGR in India, strong growth in China, and expansion in the Americas, Europe, and Asia-Pacific.